Literature DB >> 30448100

Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis.

Yaqi Li1, Yang Feng2, Weixing Dai1, Qingguo Li1, Sanjun Cai1, Junjie Peng3.   

Abstract

BACKGROUND: The prognostic value of tumor sidedness in metastatic colorectal cancer (CRC) has been established, but its impact on nonmetastatic disease remains unclear. Our study aimed to explore the prognostic effect of tumor sidedness by subgroup survival analyses, according to histology and tumor grade in stage I-IV CRCs.
METHODS: A retrospective population-based study was conducted based on Surveillance, Epidemiology and End Results (SEER) data. Population data in the SEER 9 registry (1975-2014) were used to determine survival trends of CRCs, and associated population data in the SEER 18 registry (2000 to 2014) were used to assess the prognostic impact of tumor sidedness on CRCs.
RESULTS: The 5-year cause-specific survival for all subgroups of CRCs improved from 1975 to 2014. Of 238,826 patients, 44.2% had right-sided cancer. Patients with right-sided cancer were more likely to be older, to be women, to have disease of mucinous or signet-ring cell histology, to have more poorly differentiated tumors, and to be diagnosed with a more advanced disease stage. Multivariate Cox regression showed stage I-II right-sided cancers had better cause-specific survival than the left-sided cancers (left colon: hazard ratio [HR] = 1.091, 95% confidence interval [CI], 1.052-1.132; rectum: HR = 1.363; 95% CI, 1.304-1.425; P < .001), while stage III and IV right-sided cancers had worse cause-specific survival. In subgroup analyses by histology and tumor grade within stage III CRCs, right-sided poorly differentiated mucinous adenocarcinoma showed significantly better survival (left colon: HR = 1.352; 95% CI, 1.145-1.596; rectum: HR = 1.125; 95% CI, 0.916-1.381; P = .002).
CONCLUSION: The relationship between sidedness and prognosis in CRCs depends on stage and histopathologic characteristics, especially for stage III disease.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cause specific survival; Differentiation; Histology; Stage; Surveillance, Epidemiology, and End Results program

Mesh:

Year:  2018        PMID: 30448100     DOI: 10.1016/j.clcc.2018.10.005

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


  9 in total

Review 1.  Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC).

Authors:  Ankur Bahl; Vineet Talwar; Bhawna Sirohi; Prashant Mehta; Devavrat Arya; Gunjan Shrivastava; Akhil Dahiya; K Pavithran
Journal:  Front Oncol       Date:  2020-06-16       Impact factor: 6.244

2.  Effect of sidedness on survival among patients with early-stage colon cancer: a SEER-based propensity score matching analysis.

Authors:  Zhuang-Sheng Huang; Jun-Wei Wu; Ying Li; Yu-Hai Lin; Xu-Yuan Li
Journal:  World J Surg Oncol       Date:  2021-04-19       Impact factor: 2.754

3.  Feasibility and Efficacy of Neoadjuvant Chemotherapy without Radiotherapy for Locally Advanced Rectal Cancer.

Authors:  Katsuji Tokuhara; Yuki Matsui; Yosuke Ueyama; Kazuhiko Yoshioka; Mitsugu Sekimoto
Journal:  J Anus Rectum Colon       Date:  2022-01-28

4.  Personalized Adjuvant Treatment of Colon Cancer.

Authors:  Hossein Taghizadeh; Gerald W Prager
Journal:  Visc Med       Date:  2020-06-29

5.  Impact of SARS-CoV-2 Pandemic on Colorectal Cancer Screening Delay: Effect on Stage Shift and Increased Mortality.

Authors:  Luigi Ricciardiello; Clarissa Ferrari; Michela Cameletti; Federica Gaianill; Francesco Buttitta; Franco Bazzoli; Gian Luigi de'Angelis; Alberto Malesci; Luigi Laghi
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-06       Impact factor: 11.382

6.  Cohort profile: the MCC-Spain follow-up on colorectal, breast and prostate cancers: study design and initial results.

Authors:  Jessica Alonso-Molero; Antonio J Molina; Jose Juan Jiménez-Moleón; Beatriz Pérez-Gómez; Vicente Martin; Victor Moreno; Pilar Amiano; Eva Ardanaz; Silvia de Sanjose; Inmaculada Salcedo; Guillermo Fernandez-Tardon; Juan Alguacil; Dolores Salas; Rafael Marcos-Gragera; Maria Dolores Chirlaque; Nuria Aragonés; Gemma Castaño-Vinyals; Marina Pollán; Manolis Kogevinas; Javier Llorca
Journal:  BMJ Open       Date:  2019-11-21       Impact factor: 2.692

Review 7.  Pathological Features and Prognostication in Colorectal Cancer.

Authors:  Kabytto Chen; Geoffrey Collins; Henry Wang; James Wei Tatt Toh
Journal:  Curr Oncol       Date:  2021-12-13       Impact factor: 3.677

8.  The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon.

Authors:  Kun-Han Lee; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Hung-Hsin Lin; Sheng-Chieh Huang; Hou-Hsuan Cheng; Yee Chao; Hao-Wei Teng
Journal:  Br J Cancer       Date:  2021-06-29       Impact factor: 9.075

9.  Current Perspectives on the Importance of Pathological Features in Prognostication and Guidance of Adjuvant Chemotherapy in Colon Cancer.

Authors:  Kabytto Chen; Henry Wang; Geoffrey Collins; Emma Hollands; Irene Yuen Jing Law; James Wei Tatt Toh
Journal:  Curr Oncol       Date:  2022-02-23       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.